Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

TMB-L

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related biomarkers:

‹

TMB + PD-L1 expression (0)

TMB + PD-L1 expression (0)

›

TMB-L	Melanoma	TMB-L	Melanoma	trametinib + dabrafenib + PDR001 Sensitive: B - Late Trials trametinib + dabrafenib + PDR001 Sensitive : B	trametinib + dabrafenib + PDR001 Sensitive: B - Late Trials trametinib + dabrafenib + PDR001 Sensitive : B
TMB-L	Follicular Lymphoma	TMB-L	Follicular Lymphoma	rituximab Sensitive: B - Late Trials rituximab Sensitive : B	rituximab Sensitive: B - Late Trials rituximab Sensitive : B
TMB-L	Colorectal Cancer	TMB-L	Colorectal Cancer	durvalumab + tremelimumab-actl Sensitive: C3 – Early Trials durvalumab + tremelimumab-actl Sensitive : C3	durvalumab + tremelimumab-actl Sensitive: C3 – Early Trials durvalumab + tremelimumab-actl Sensitive : C3
TMB-L	Adrenal Cortex Carcinoma	TMB-L	Adrenal Cortex Carcinoma	mitotane Sensitive: C3 – Early Trials mitotane Sensitive : C3	mitotane Sensitive: C3 – Early Trials mitotane Sensitive : C3
TMB-L	Malignant Pleural Mesothelioma	TMB-L	Malignant Pleural Mesothelioma	PD1 inhibitor Resistant: C3 – Early Trials PD1 inhibitor Resistant : C3	PD1 inhibitor Resistant: C3 – Early Trials PD1 inhibitor Resistant : C3
TMB-L	Malignant Pleural Mesothelioma	TMB-L	Malignant Pleural Mesothelioma	PD-L1 inhibitor Resistant: C3 – Early Trials PD-L1 inhibitor Resistant : C3	PD-L1 inhibitor Resistant: C3 – Early Trials PD-L1 inhibitor Resistant : C3
TMB-L	Glioblastoma	TMB-L	Glioblastoma	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
TMB-L	Non Small Cell Lung Cancer	TMB-L	Non Small Cell Lung Cancer	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3
TMB-L	Non Small Cell Lung Cancer	TMB-L	Non Small Cell Lung Cancer	durvalumab + tremelimumab-actl Resistant: C3 – Early Trials durvalumab + tremelimumab-actl Resistant : C3	durvalumab + tremelimumab-actl Resistant: C3 – Early Trials durvalumab + tremelimumab-actl Resistant : C3
TMB-L	Pancreatic Cancer	TMB-L	Pancreatic Cancer	nivolumab + BMS-986227 Sensitive: C3 – Early Trials nivolumab + BMS-986227 Sensitive : C3	nivolumab + BMS-986227 Sensitive: C3 – Early Trials nivolumab + BMS-986227 Sensitive : C3
TMB-L	Lung Cancer	TMB-L	Lung Cancer	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3
TMB-L	Gastric Cancer	TMB-L	Gastric Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3